Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211808 · ClinicalTrials.gov registry record · Phase 1
Effect of Diltiazem on Pharmacokinetics of BMS-914392
A Phase 1 study of Atrial Fibrillation, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01211808 is a Phase 1 study of Atrial Fibrillation that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01211808, a Phase 1 study of Atrial Fibrillation, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
Conditions Studied
Interventions
- DRUG Diltiazem
- DRUG BMS-914832
Study Locations (1)
Kansas
- Pra International - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-09 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211808
The ClinicalTrials.gov registry entry for NCT01211808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Diltiazem is the first listed.
NCT01211808 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01211808 about?
NCT01211808 is a clinical study titled "Effect of Diltiazem on Pharmacokinetics of BMS-914392". The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
What is the current status of trial NCT01211808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-09. Estimated completion is 2010-10.
What conditions does trial NCT01211808 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT01211808?
The interventions under investigation include: Diltiazem (DRUG), BMS-914832 (DRUG).
Who is sponsoring clinical trial NCT01211808?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01211808 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Synaptic Plasticity in the Epicardial Ganglionated Plexi
RECRUITING · Phase 1
-
Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study
COMPLETED · Phase 1
-
Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
COMPLETED · Phase 1
-
Stroke Feasibility Study
COMPLETED · Phase 1
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.